Licensure & Accreditations🔒 SSL VerifiedWelcome to the detailed analysis for mdxhealth.com. This domain is officially recognized as Home - mdxhealth. According to their official web presence, their primary focus is: "Improving the earlier detection of aggressive prostate cancer and urologic diseases with personalized molecular diagnostic solutions Learn more Recent Webinars https://youtu.be/N_Wq2NDi7yw?si=AMdqaCYLu5Ef8RsJ From Genomics to Risk Scores: Integrating GPS mdx Across CAPRA-Based Clinical Decision-Making Following an overview of the study, an expert panel will share cross-institutional perspectives on the clinical utility and real-world application of GPS […]".
By comparing mdxhealth.com to other leading websites in its niche, marketers and researchers can identify key traffic sources and growth opportunities. Explore our related resources below to find websites similar to mdxhealth.com.
Yes, according to our latest analysis, we detected a valid SSL certificate ensuring a secure connection.
As of September 27, 2026, mdxhealth.com holds an estimated domain authority score of 54/100 based on our VisitRank tracking algorithms.
You can find the best alternatives and similar sites to mdxhealth.com in our explore section, which includes competitors in the E-commerce & Retail sector.
Common Misspellings & Typo Domains for mdxhealth.com:
"Following an overview of the study, an expert panel will share cross-institutional perspectives on the clinical utility and real-world application of GPS mdx in prostate cancer risk stratification."
"Watch Dr. Jose De La Cerda, a urologist with extensive experience integrating Confirm mdx alongside modern imaging and biopsy techniques, as he discusses the science behind Confirm mdx and shares his real-world clinical approach to patient management based on Confirm mdx positive and negative results."
"Learn how Dr. James Kearns consistently uses MRI + Confirm mdx for complete prostate cancer risk assessment."
"Join the experts, Dr. Vip Patel, Dr. Marcio Covas-Moschovas, and Dr. Brooks, as they synthesize data from three notable studies establishing the definitive link between the Genomic Prostate Score (GPS), Adverse Pathology (AP), and 20-year patient survival."